Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate

Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I, Lancet M

doi:10.1016/0002-9378(85)90141-3

Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate

M Yemini, Ρ Borenstein, B.M. Mogilner, Z Apelman, R Borenstein, E Dreazen, I Kessler, M Lancet

Kaplan Medical Center ROR
Department of Obstetrics and Gynecology, Kaplan Hospital, Rehovot, Israel.

American Journal of Obstetrics and Gynecology, 151(5), 574-577

DOI 10.1016/0002-9378(85)90141-3 PMID 3976757

Abstract

Eighty pregnant women at high risk of giving birth prematurely were divided randomly into two groups. Treatment with either 17 alpha-hydroxyprogesterone caproate, 250 mg by intramuscular injection once a week, or a placebo was given in a double-blind fashion. Imminent premature labor occurred in 29.0% of the treated group and in 59.4% of the control group (p less than 0.025). The rate of premature deliveries was also significantly lower in the treated group (16.1%) than in the control group (37.82%) (p less than 0.05). There were no cases of perinatal death or fetal malformations in either group. The mean birth weight of all infants of the treated group was significantly higher than in those of the control group (3111.9 +/- 905 gm versus 2680 +/- 813.4 gm, p less than 0.05). The results support treatment with progesterone caproate for the prevention of premature labor.

Topics

Pregnancy > Preterm Labor > Progesterone Prevention Pregnancy > Medications in Pregnancy > 17-OHPC Research Methodology > Clinical Trials > Randomized Controlled Trials

17 alpha-hydroxyprogesterone caproate preterm labor prevention, progesterone supplementation premature birth randomized trial, 17-OHPC injection preterm delivery high risk pregnancy, Yemini progesterone caproate premature labor prevention, intramuscular progesterone preterm birth double-blind trial, weekly progesterone injection premature labor reduction, progestogen therapy high risk premature delivery, hydroxyprogesterone caproate birth weight preterm outcomes, progesterone supplementation pregnancy preterm prevention RCT, premature labor prophylaxis progesterone efficacy

PMID 3976757 3976757 DOI 10.1016/0002-9378(85)90141-3 10.1016/0002-9378(85)90141-3

Cite this article

Yemini, M., Borenstein, R., Dreazen, E., Apelman, Z., Mogilner, B. M., Kessler, I., & Lancet, M. (1985). Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. *American journal of obstetrics and gynecology*, *151*(5), 574-577. https://doi.org/10.1016/0002-9378(85)90141-3

Keywords

17-alpha-Hydroxyprogesterone, Adult, Birth Weight, Double-Blind Method, Female, Humans, Hydroxyprogesterones/therapeutic Use, Infant Mortality, Infant, Newborn, Infant, Premature, Obstetric Labor, Premature/prevention & Control, Pregnancy, Random Allocation, Hydroxyprogesterones, 17-alpha-Hydroxyprogesterone

Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate

Abstract

Topics

Cite this article

Keywords

Related articles

A placebo-controlled double-blind randomized trial of the use of combined l-carnitine and l-acetyl-carnitine treatment in men with asthenozoospermia

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

Incident endometriosis diagnosis and anti-müllerian hormone (AMH): how surgical staging and typology relate to serum AMH levels

"Uterine closure after cesarean delivery: surgical technique, biological rationale, and clinical implications."